Background. Hyperkalaemia is common in patients with advanced renal disease. In this double-blind, randomized, three-sequence, crossover study, we compared the effect of three dialysate bicarbonate concentrations ([HCO 3 À ]) on the kinetics of serum potassium (K þ ) reduction during a conventional haemodialysis (HD) session in chronic HD patients. Methods. We studied eight stable HD patients. The choice of dialysate [HCO 3 À ] followed a previously assigned treatment protocol and the [HCO 3 À ] used were low bicarbonate (LB; 27 mmol/l), standard bicarbonate (SB; 35 mmol/l) and high bicarbonate (HB; 39 mmol/l). Polysulphone dialysers and automated machines provided blood flow rates of 300 ml/min and dialysis flow rates of 500 ml/min for each HD session. Blood samples were drawn at 0 (baseline), 15, 30, 60 and 240 min from the arterial extracorporeal line to assess blood gases and serum electrolytes. In three of the eight patients, we measured serum K þ 1 h post-dialysis as well as K þ removal by the dialysis. The same procedures were followed until the completion of the three arms of the study, with a 1 week interval between each experimental arm. À ] was associated with a faster decrease in serum K þ . Our results strongly suggest that this reduction was due to the enhanced shifting of K þ from the extracellular to the intracellular fluid compartment rather than its removal by dialysis. This finding could have an impact for those patients with life-threatening pre-HD hyperkalaemia.
Introduction
Hyperkalaemia is one of the most frequent lifethreatening electrolyte disorders in patients with advanced renal disease [1] .
The conservative emergency treatment of this condition includes intravenous calcium gluconate, infusion of insulin along with glucose, nebulized b 2 adrenergic agonists, intravenous NaHCO 3 and oral or rectal cation-exchange resins [2] .
Although NaHCO 3 is used widely for the treatment of emergency hyperkalaemia, its effect is uncertain and several authors have reported that varying bicarbonate infusion rates failed to lower serum potassium (K þ ) in hyperkalaemic patients with end-stage renal disease (ESRD) [3] [4] [5] .
Conventional haemodialysis (HD) is highly efficient in removing the excess of body K þ , decreasing the serum K þ concentration ([K þ ]) and, thus, restoring the resting membrane potential, which is vital for normal neuromuscular function and myocardial activity [4] .
In severely hyperkalaemic patients, the faster the [K þ ] is lowered, the faster the recovery from related serious conditions, such as cardiac arrhythmia.
Patients with ESRD also have metabolic acidosis, the degree of which depends upon several factors: interdialytic protein intake, protein catabolic rate, the length and frequency of HD sessions and the type and magnitude of the buffer in the dialysate.
The most widely utilized buffer in HD is bicarbonate, which corrects the acidosis that develops during the interdialytic period. The improvement of acidaemia might allow the transfer of K þ into the cellular compartment; thus, part of the effect of the bicarbonate buffer on serum K þ could be due to a transcellular shift [6] .
To our knowledge, no data exist in the medical literature on the effects on serum K þ levels of different dialysate bicarbonate concentrations ([HCO 3 À ]) administered during dialysis.
The aim of this study was to compare the effects of three different dialysate [HCO 3 À ] (27, 35 and 39 mmol/l) on the kinetics of the reduction of [K þ ] during conventional HD in ESRD patients.
Subjects and methods

Design
This is a double-blind (patient and laboratory technician), randomized, three-sequence, crossover study comparing the effect of three different dialysate [HCO 3 À ] [low (LB), 27 mmol/l; standard (SB), 35 mmol/l; and high (HB), 39 mmol/l] on the kinetics of the reduction of [K þ ] during a standard HD session in ESRD patients on chronic (thrice weekly) HD. The participants went through one of the three treatment sequences (1: LB, SB, HB; 2: SB, HB, LB; and 3: HB, LB, SB), having been assigned according to a previously designed random-digit table. Three patients received sequence 1, three sequence 2 and two sequence 3.
Inclusion and exclusion criteria
The patients admitted into the study were adults with ESRD who were treated with regular (12 h/week) HD in the Unidad de Nefrologı´a, Hospital Juan A. Ferna´ndez, Buenos Aires, Argentina, for at least the preceding 12 months. Subjects had to have a permanent native arteriovenous fistula or a polytetrafluorethylene prosthetic vascular access allowing a Qb !280 ml/min and be without any relevant associated medical disorder for !3 months prior to the study. Patients with one or more of the following conditions were excluded: diabetes, haemolytic diseases, rhabdomyolysis, hepatic necrosis, neoplasms, dyskalaemic periodic paralysis, chronic obstructive lung disease, haemodynamic instability, hypercalcaemia, intolerance to bicarbonate dialysate, extra-skeletal calcifications, chronic diarrhoea, intestinal by-pass, malabsorptive disorders, enteric fistulas or villous adenoma.
Patients receiving drugs that could modify internal K þ balance or K þ excretion (i.e. b-blockers, diuretics, angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonists, non-steroidal anti-inflammatory drugs, b 2 agonists, trimethoprim, pentamidine, stool softeners, cathartics or insulin) and those requiring hypertonic dextrose solutions or mannitol infusion during HD were also excluded.
An Institutional Review Board and Ethics Committee (Comisio´n de Evaluacio´n de Ensayos Clı´nicos, Departamento de Docencia e Investigacio´n. Hospital Juan A. Fernandez) approved the study protocol, which conforms to the provisions of the World Medical Association's declaration of Helsinki and the World Medical Assembly of Tokyo (1975) . All the participants gave their signed consent prior to enrolment.
Patients and procedures
Upon arrival of a subject for a regular HD session, the vascular access was punctured with two standard HD fistula needles and 1 ml blood was collected anaerobically in heparinized plastic syringes from the arterial side of the extracorporeal line to measure baseline blood gases,
]. Then, and immediately before starting HD, the dialysate [HCO 3 À ] (27, 35 or 39 mmol/l) was selected according to the previously randomly assigned treatment sequence, as described above.
Polysulphone hollow-fibre dialysers (Fresenius F-7, surface area 1.6 m 2 ; Fresenius) and dialysis machines providing the dialysate automatically (Baxter 1550; Baxter Corp., IL) were used with a Qb of 300 ml/min and a Qd of 500 ml/min in each HD session.
The final HD fluid composition (mmol/l) was Na 140, ] was obtained by modifying the dialyser's delivery system and the concentration of Cl À varied reciprocally. Discretionary extra-corporeal heparinization was allowed during HD, administered through an automatic pump system. Sequential blood samples were drawn from the arterial side of the extracorporeal line (as described previously) at 15, 30, 60 and 240 min. In three of the eight subjects, additional blood samples were drawn 1 h after HD to assess potassium rebound.
The same procedures were followed until the completion of the three arms of the study. A washout period of !1 week was allowed between experiments, with the participants receiving their usual dialysis sessions between them.
Blood sample processing
All intradialysis blood samples were drawn from the rubber socket of the arterial extracorporeal line before blood passed through the dialyser and they were submitted to the laboratory immediately for analysis.
In the laboratory, 100 ml whole blood was injected into an automatic analyser (OMNI; AVL Scientific Corp., Roswell, GA). 
Dialysate processing
In the three patients in whom K þ rebound was studied, we assessed the removal of K þ by dialysis. For this, the dialysate was collected in a cylindrical reservoir. Four sequential samples (0-15, 15-30, 30-60 and 60-240 min) were taken.
Each sample, and the total of the four samples were weighed, and a relationship of 1 g ¼ 1 ml was assumed.
The concentration of potassium was measured in the inflow and collected dialysate and K þ removal was calculated as: 
Adverse experiences
Any adverse experience during this trial was documented.
Statistical analysis
All values are expressed as means±SEM. The Shapiro-Wilk test was performed in order to determine if the data were normally distributed. One-way and repeated measures analysis of variance (ANOVA) in both factors (time and treatments) were used, with a posteriori StudentNewman-Keuls analyses when appropriate. Simple linear regressions and correlations were also used to examine the relationship between the change (Á) in [HCO 3 À ] and Á[K þ ]. All the tests were two-tailed and P-values of <0.05 were accepted as statistically significant.
Results
We studied eight anuric ESRD patients (46±4.9 years old), with a dry weight of 70.3±8.0 kg, on chronic HD for 66±13.5 months. During the 3 months preceding their enrolment, their haematocrits were stable (29.5±2.7%), their interdialytic weight gain varied from 1.8 to 5.5 kg (3.26±0.43 kg), their calcium Â phosphorus product ranged from 33. 6 (Figure 2 ). Ionic calcium levels remained within the normal range throughout the study with each of the three treatment arms (1.05±0.05, 1.13±0.06 and 0.98± 0.06 mmol/l for LB, SB and HB dialysis, respectively, at baseline and 1.2±0.03, 1.08±0.04 and 1.02± 0.07 mmol/l for LB, SB and HB, respectively, at the end of dialysis).
Data on blood pressure are provided in Figure 3 . Both systolic and diastolic pressures decreased during the dialysis sessions with the three treatments. This reduction was statistically significant but not clinically. Similarly, there were no significant changes in heart rate under the three experimental conditions.
No adverse events were recorded at all, severe alkalenia was not evident after HD with HB and no cardiac arrhythmia was documented clinically.
In three out of the eight patients, plasma K þ was also measured 1 h after HD. Plasma K þ rose slightly from 3.5±0.25 to 3.8±0.23 mmol/l (HB), from 3.67±0.22 to 3.83±0.12 mmol/l (SB) and from 3.8±0.25 to 3.9± 0.17 mmol/l (LB) 1 h after the end of HD; therefore, K þ rebound (%) was 8.9±4.9 (HB), 5.2±6.6 (SB) and 3.9±10.2 (LB). This rebound was slight and statistically not significant when the three treatment schedules were compared. This absence of statistically significant differences may well be due to the small number of patients in whom potassium rebound was studied.
Potassium removal by HD
In the same three patients in whom K þ rebound was assessed, we also measured K þ removal by dialysis. Although no statistically significant differences were found, the total amount of K þ removed by HD was higher during treatment with LB than with SB or HB Figure 4 . Potassium removal with the 27 mmol/l [HCO 3 À ] dialysate was associated with the lowest K þ rebound (3.9±10.2%; P ¼ NS).
Discussion
Hyperkalaemia is one of the most frequent lifethreatening electrolyte disturbances in patients suffering from advanced renal failure, and HD is the most effective approach to reduce [K þ ] in them [4] . This study demonstrates that HD with high concentrations of dialysate bicarbonate caused a faster decrease in serum K þ than dialysates with lower bicarbonate content. À and concluded that K þ was not significantly affected. In that study, only one HCO 3 À concentration was used and blood samples were taken only pre-and post-HD.
The main aim of our work was to study the kinetics of K þ and changes of acid-base balance using different dialysate [HCO 3 À ]. Plasma [K
